Reports of lower respiratory tract infection following dose 1 of RotaTeq and Rotarix vaccines to the Vaccine Adverse Event Reporting System (VAERS), 2008–2016
| Autor: | Eric Weintraub, Muhammad Amin, Carmen Ng, Penina Haber, Michael M. McNeil |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Pharmacology
Vaccine safety medicine.medical_specialty Respiratory tract infections business.industry Immunology medicine.disease medicine.disease_cause urologic and male genital diseases Rotavirus vaccine 03 medical and health sciences Adverse Event Reporting System 0302 clinical medicine 030225 pediatrics Lower respiratory tract infection Rotavirus Internal medicine Epidemiological surveillance Immunology and Allergy Medicine 030212 general & internal medicine business Adverse effect Research Paper |
| Popis: | A 2018 manufacturer post-licensure safety study identified a possible association between Rotarix (RV1) rotavirus vaccine and lower respiratory tract infections (LRTI) in infants within 0-6 days following receipt of RV1 dose 1. We reviewed reports to the Vaccine Adverse Event Reporting System (VAERS) of LRTI occurring 0-6 days and 0-29 days post vaccination following RotaTeq (RV5) or Rotarix (RV1) vaccinations in conjunction with either Prevnar (PCV7) or Prevnar 13 (PCV13), in infants aged 6 to 15 weeks. There was no significant difference in LRTI reports to VAERS in the 0-6 days and 0-29 days following receipt of either RV5 or RV1 given with either pneumococcal vaccine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|